Am J Pediatr Hematol Oncol. 1983;5(2):161-71.

Childhood non-Hodgkin's lymphoma: prognostic relevance of clinical stages and histologic subgroups.

The American journal of pediatric hematology/oncology

M Gasparini, F Lombardi, C Gianni, A Lattuada, F Rilke, F Fossati-Bellani

PMID: 6412581

Abstract

Seventy-nine consecutive children with non-Hodgkin's lymphoma were treated with a uniform intensive radiotherapy-chemotherapy program including high-dose MTX and CNS prophylaxis. Burkitt-type NHL was diagnosed in 44% and convoluted cell-type NHL in 33%. Complete remission rate was 97.5%. Forty-eight of 79 children (61%) remain progression-free after 18-78 months of follow-up. Patients belonging to the Burkitt type subgroup showed a peculiar clinical behavior as well as a significantly shorter survival than the other NHL patients (3-year overall survival rates of 50% vs. 72%, respectively). Clinical stages were related to the progression-free survival. It is concluded that treatment should be tailored according to the histology (Burkitt-type NHL vs. other histologic types) and the clinical stage.

Substances

• Antineoplastic Agents

MeSH terms

• Adolescent
• Antineoplastic Agents / administration & dosage
• Burkitt Lymphoma / mortality
• Burkitt Lymphoma / therapy
• Child
• Child, Preschool
• Drug Therapy, Combination
• Female
• Humans
• Infant
• Lymphoma / mortality
• Lymphoma / therapy
• Male
• Neoplasm Staging
• Prognosis
• Radiotherapy, High-Energy
• Time Factors

Publication Types

• Journal Article

LinkOut - more resources

• Full Text Sources
  • Ovid Technologies, Inc.
• Medical
  • Genetic Alliance